Compare Crispr Therapeutics AG (CRSP) vs Seagate Technology Holdings PLC (STX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Seagate Technology Holdings PLC — how do they compare? Crispr Therapeutics AG trades at $53.51 (market cap $4.88B), while Seagate Technology Holdings PLC trades at $782.94 (market cap $176.19B). The key difference: Seagate Technology Holdings PLC is far larger — about 36.1× Crispr Therapeutics AG's market cap, and Seagate Technology Holdings PLC pays a 0.38% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Seagate Technology Holdings PLC for 41 Days on average.
| CRSP | STX | |
|---|---|---|
Market Cap | $4.88B | $176.19B |
Volume | 2,861,747 | 5,061,875 |
Sector | Health | Technology |
52-Week High | $74.92 | $1.09K |
52-Week Low | $44.34 | $211.63 |
Typical Hold Time | 77 Days | 41 Days |
Enterprise Value | $3.30B | $178.34B |
Dividend Yield | — | 0.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.41, up 2.02% with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with -$581.60M net income in 2025 and revenue volatility, though analyst consensus remains bullish with a $67.83 price target. Key catalysts include upcoming clinical data presentations for autoimmune disease therapies and CASGEVY commercialization progress.
The stock presents high-risk, high-reward potential with strong Wall Street support (57.9% buy ratings) but faces significant execution risks. Near-term performance hinges on clinical trial outcomes and revenue generation from approved therapies, while persistent cash burn and competitive pressures remain key concerns for investors.
Seagate Technology (STX) trades at $780.39, down 3.34% amid concerns about increased competition from Toshiba's planned HDD production expansion. The stock shows strong fundamental performance with Q2 2026 EPS beating expectations at $5.71 versus $5.10, and maintains robust profitability with 26.11% net margin and 371.53% ROE. Technical indicators signal bearish momentum with price below key pivot points, though RSI suggests potential oversold conditions at 24.89.
Despite near-term competitive pressures, Seagate's dominant position in AI storage and strong earnings trajectory support long-term growth. The consensus price target of $1,130 represents 45% upside potential, but investors face risks from pricing pressure and market share erosion as Toshiba expands capacity in 2027.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Seagate Technology Holdings PLC
Seagate is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital
Read more on STX →
